CLINICAL ROLE -
Oncology Overview: Sacituzumab Govitecan-hziy (Trodelvy) for Triple-Negative Breast Cancer
Sacituzumab govitecan-hziy (Trodelvy) is indicated for the treatment of patients with triple-negative breast cancer who have received 2 prior therapies at minimum for metastatic disease.
Oncology Overview: Enfortumab vedotin-ejfv for Advanced or Metastatic Urothelial Cancer
Enfortumab vedotin-ejfv (Seagen; Padcev) is a first-in-class antibody-drug conjugate approved for patients with previously treated locally advanced or metastatic urothelial cancer.
2 Clarke Drive Cranbury, NJ 08512